Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZozaya, Néboa-
dc.contributor.authorCaballero, Teresa-
dc.contributor.authorGonzález Quevedo, Teresa-
dc.contributor.authorGamboa Setien, Pedro-
dc.contributor.authorGonzález, M. Ángeles-
dc.contributor.authorJódar Masanés, Ramón José-
dc.contributor.authorPoveda Andrés, José Luis-
dc.contributor.authorGuillén Navarro, Encarna-
dc.contributor.authorRivero Cuadrado, Agustín-
dc.contributor.authorHidalgo Vega, Álvaro-
dc.description.abstractIntroduction: Hereditary angioedema (HAE) is a rare genetic disease that impairs quality of life and could be life-threatening. The aim of this study was to apply a multicriteria decision analysis to assess the value of three long-term prophylactic (LIP) therapies for HAE in Spain. Methods: A multidisciplinary committee of 10 experts assessed the value of lanadelumab (subcutaneous use), C1-inhibitor (C1-INH; intravenous), and danazol (orally), using placebo as comparator. We followed the EVIDEM methodology that considers a set of 13 quantitative criteria. The overall estimated value of each intervention was obtained combining the weighting of each criterion with the scoring of each intervention in each criterion. We used two alternative weighting methods: hierarchical point allocation (HPA) and direct rating scale (DRS). A reevaluation of weightings and scores was performed. Results: Lanadelumab obtained higher mean scores than C1-INH and danazol in all criteria, except for the cost of the intervention and clinical practice guidelines. Under the HPA method, the estimated values were 0.51 (95% confidence interval [CI]: 0.44-0.58) for lanadelumab, 0.47 (95%CI: 0.41-0.53) for C1-INH, and 0.31 (95%CI: 0.240.39) for danazol. Similar results were obtained with the DRS method: 0.51 (95%CI: 0.42-0.60), 0.47 (95%CI: 0.40-0.54), and 0.27 (95%CI: 0.18-0.37), respectively. The comparative cost of the intervention was the only criterion that contributed negatively to the values of lanadelumab and C1-INH. For danazol, four criteria contributed negatively, mainly comparative safety. Conclusion: Lanadelumab was assessed as a high-value intervention, better than C1-INH and substantially better than danazol for LTP treatment of HAE.-
dc.format.extent8 p.-
dc.publisherAboutscience Srl-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofGlobal & Regional Health Technology Assessment, 2022, vol. 9, p. 14-21-
dc.rightscc by-nc (c) Zozaya, Néboa et al., 2022-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalalties rares-
dc.subject.classificationMalalties hereditàries-
dc.subject.classificationAssaigs clínics de medicaments-
dc.subject.otherRare diseases-
dc.subject.otherGenetic diseases-
dc.subject.otherDrug testing-
dc.titleA multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
GRHTA_2333_2022_14-21.pdf1 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons